RE:RE:RE:Most important news release to dateMy apologies, I wasn't trying to pass off as new news. I thought saying most important news release to date was self-explanatory. I'm surprised everyone doesn't know where this came from because it came directly from canopy growth website. With so much going on with this company it's easy to forget about important information like this news release. We are inundated on this board with negative rhetoric from all the Bashers and shorts and I think it's important to remind ourselves why we're here and why we believe in this company.
Bird1splitter wrote: This is old news
RainbowRunner wrote: Where’d you find this, 55? What’s the date on it? Thanks.
55orbust wrote: Canopy Health Innovations (Canopy Health or CHI), the partly-owned biopharmaceutical research and development affiliate of Canopy Growth Corporation (TSX: WEED) (Canopy Growth), today announced that it has, alone or with its subsidiary Canopy Animal Health or through its joint-venture Beckley Canopy Therapeutics, filed eight provisional US patents pertaining to the delivery and application of cannabis and cannabinoid-based therapeutics in certain indications. Specifically, the eight patent applications relate to the following: Fibromyalgia Amyotrophic Lateral Sclerosis (also known as ALS, Lou Gehrigs disease) Anxiety and its various sub-groups (in humans and animals, in conjunction with Canopy Animal Health) Cognitive enhancement (in humans and animals, in conjunction with Canopy Animal Health) Pain and various sub-groups (in humans and animals, in conjunction with Canopy Animal Health) Opioid sparing, pain management, and addiction (through Beckley Canopy Therapeutics) Addiction and smoking cessation (through Beckley Canopy Therapeutics) A platform and method for delivery of cannabis-based compositions In addition to updated applications relating to earlier Insomnia patent applications, this brings the total number of US provisional patent filings (including Canopy Animal Health and Beckley Canopy Therapeutics) to thirty-nine. Canopy Health and its affiliates continue their practice of filing provisional patents in the United States, which is common in the field of intellectual property generation and protection. Patents are first filed in the United States to create a priority date and allow for future filings in other selected jurisdictions, including Canada. Although cannabis is not presently federally legal in the United States for commercial purposes, it is still the most common first to file jurisdiction for intellectual property generation and protection activity pertaining to cannabis and cannabinoids. Heres to Future Growth.